A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer

Cancer Research

Volumn 71, Issue 21, 2011, Pages 6773-6784

  Fox, Emily M ^a   Miller, Todd W ^a   Balko, Justin M ^a   Kuba, Maria G ^a   Sánchez, Violeta ^a   Smith, R Adam ^a,b   Liu, Shuying ^c   González Angulo, Ana María ^c   Mills, Gordon B ^c   Ye, Fei ^a   Shyr, Yu ^a   Manning, H Charles ^a,b   Buck, Elizabeth ^d   Arteaga, Carlos L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d OSI PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FULVESTRANT; INSULIN RECEPTOR; LETROZOLE; LINSITINIB; MAB 391; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LONG TERM CARE; MONOTHERAPY; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROTEIN-TYROSINE KINASES; PYRAZINES; RANDOM ALLOCATION; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; RECEPTORS, ESTROGEN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80155131176     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1295     Document Type: Article

References (47)

1. Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 2010;7:11-24.
2. Belfiore A, Frasca F. IGFand insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:381-406.
3. Papa V, Pezzino V, Costantino A, Belfiore A,Giuffrida D, Frittitta L, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990;86:1503-10. (Pubitemid 20372597)
4. Papa V, Gliozzo B, Clark GM,McGuire WL, Moore D, Fujita-Yamaguchi Y, et al. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993;53: 3736-40. (Pubitemid 23252035)
5. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999;5:1935-44. (Pubitemid 29334478)
6. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, et al. Compensatory insulin receptor (IR) activation on inhibition of insulinlike growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 2010;9:2652-64.
7. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, et al. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008;68:10238-46.
8. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol Neoplasia 2008;13:471-83.
9. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 2010;70:741-51.
10. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.
11. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004;10:5670-6. (Pubitemid 39180941)
12. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741-8. (Pubitemid 41557193)
13. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-13.
14. Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008;13: 91-104. (Pubitemid 351163160)
15. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinibsensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005;102:3788-93. (Pubitemid 40354690)
16. McKinley ET, Bugaj JE, Zhao P, Guleryuz S, Mantis C, Gokhale PC, et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res 2011;17:3332-40.
17. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006;5:2512-21. (Pubitemid 44650915)
18. Hennessy B, Lu Y, Gonzalez-Angulo A, Carey M, Myhre S, Ju Z, et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 2010;6:129-51.
19. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99:167-70.
20. Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009;1:1153-71.
21. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004;5:231-9. (Pubitemid 38402115)
22. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 2007;6:2158-67. (Pubitemid 47294744)
23. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-40. (Pubitemid 47583908)
24. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006;66:362-71. (Pubitemid 43166043)
25. Rosenfeld-Franklin M, Cooke A, Pirritt C, Landfair D, Silva S, Turton R, et al. In vivo evaluation of OSI-906, a novel small molecule kinase inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). In: AACRNCI-EORTC Molecular Targets and Cancer Therapeutics Meeting; San Franscisco, CA; 2007.
26. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 2005;65:5439-44. (Pubitemid 40827357)
27. Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 2002;81:333-41. (Pubitemid 35279118)
28. Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000;5:107-15.
29. Zha J, O'Brien C, Savage H, Huw LY, Zhong F, Berry L, et al. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 2009;8:2110-21.
30. Martin LA, Pancholi S, Chan CM, Farmer I, Kimberley C, Dowsett M, et al. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 2005;12:1017-36. (Pubitemid 41815794)
31. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010;28:4111-9.
32. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008;9:239.
33. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008;26:4078-85.
34. Tamayo P, Scanfeld D, Ebert BL, Gillette MA, Roberts CW, Mesirov JP. Metagene projection for cross-platform, cross-species characterization of global transcriptional states. Proc Natl Acad Sci U S A 2007;104:5959-64. (Pubitemid 47175641)
35. Allison DB, Cui X, Page GP, Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 2006;7:55-65. (Pubitemid 41828948)
36. Efron B, Tibshirani R. On testing the significance of sets of genes. Ann Appl Stat 2007;1:107-29.
37. Loboda A, Nebozhyn M, Cheng C, Vessey R, Huang P, Dai H, et al. Biomarker discovery: identification of a growth factor gene signature. Clin Pharmacol Ther 2009;86:92-6.
38. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008;68:826-33. (Pubitemid 351206760)
39. Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI. Insulinlike growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005;146:4609-18. (Pubitemid 41446598)
40. Lindsay CR, Chan E, Evans TR, Campbell S, Bell P, Stephens AW, et al. Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 27:15s, 2009 (suppl; abstr 2559).
41. Carden CP, Kim ES, Jones RL, Alam SM, Johnson FM, Stephens AW, et al. Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 2530).
42. Evans T, Lindsay CR, Chan E, Tait B, Michael SA, Day S, et al. Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 2531).
43. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A 2010;107:10791-8.
44. Kaufman P, Ferrero J, Bourgeois H, Kennecke H, De Boer R, Jacot W, et al. A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC) [abstract]. Cancer Res 2011;70: S1-4.
45. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011;30:2730-40.
46. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007;67:391-7. (Pubitemid 46142798)
47. Fulzele K, DiGirolamo DJ, Liu Z, Xu J, Messina JL, Clemens TL. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J Biol Chem 2007; 282:25649-58. (Pubitemid 47372844)